本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股东股份质押基本情况 吉林敖东药业集团股份有限公司（以下简称"公司"）接到股东敦化市金诚 实业有限责任公司（以下简称"金诚公司"）函告，获悉金诚公司所持有公司的 部分股份办理质押及解除质押手续，具体事项如下： （一）股东股份质押 1、股东股份质押基本情况 | 股东名称 | 是否为控股 股东或第一 | 本次质押 | 占其所持 | 占公司总 | 是否 | 是否为 | | | | 质押 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 大股东及其 | 数量(万 | 股份比例 | 股本比例 | 为限 | 补充质 | 质押起始日 | 质押到期日 | 质权人 | 用途 | | | 一致行动人 | 股) | | | 售股 | 押 | | | | | | 敦化市金 诚实业有 | | | | | | | 2025 年 6 月 | 质押期限至 其办理解除 | 上海海通 证券资产 | 经营 | | | 是 | 1,093.75 | 3 ...

证券代码：000623 证券简称：吉林敖东 公告编号：2025-032 吉林敖东药业集团股份有限公司 关于控股子公司获得药品补充申请批准通知书 的自愿性信息披露公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，吉林敖东药业集团股份有限公司（以下简称"公司"）控股子公司吉 林敖东药业集团延吉股份有限公司（以下简称"延吉药业"）收到国家药品监督 管理局下发的"糖乐胶囊"的《药品补充申请批准通知书》。现就相关情况公告 如下： 一、《药品补充申请批准通知书》的主要内容 1．糖乐胶囊 药品通用名称：糖乐胶囊 剂型：胶囊剂 规格：每粒装0.3g 注册分类：中药 受理号：CYZB2500952 通知书编号：2025B02585 原药品批准文号：国药准字Z20025227 上市许可持有人名称：吉林敖东药业集团延吉股份有限公司 上市许可持有人地址：吉林省延吉市高新技术开发区长白路389号 生产企业名称：吉林省德商药业股份有限公司 生产企业地址：吉林省辉南县经济开发区北一街 申请内容：其他：变更糖乐胶囊（国药准字Z20025227）的上市许可持有人， 主体由吉林省德商药 ...

年 蜂蜜类保健食品行业词条报告 食品加工/保健品 港股分类法/ /食品饮料、申万分类/食品饮料/ Copyright © 2025 头豹 蜂蜜类保健食品：天然健康趋势下的百亿市场扩容与创新机遇 头豹 词条报告系列 钟琪 · 头豹分析师 2025-05-30 未经平台授权，禁止转载 行业分类： 食品饮料/保健品 摘要 蜂蜜类保健食品以蜂蜜为主要原料，具有多种药理作用。当前，原料质量参差不齐，要求中游企业建立严格筛选和检测机制。行业监管边界清晰，旨在保障消费者健康。随 着健康意识提升和人口老龄化，市场需求持续旺盛。然而，技术创新滞后和替代品竞争压力导致市场规模增长乏力。未来，人口老龄化将推动市场需求增长，政策支持和行 业创新发展将为行业奠定坚实基础，预计市场规模将稳步增长。 蜂蜜类保健食品是以蜂蜜为主要原料的保健食品。蜂蜜是由意大利蜜蜂或中华蜜蜂等蜜蜂科昆虫所酿的花蜜，是蜜蜂从植物活体上或植物活 体分泌物中吸收植物花粉并与自身分泌物结合后，经充分转化、脱水，在蜂巢中存放酿造待成熟后形成的物质。蜂蜜是药理作用广泛的常用中 药，具有补中润燥、止痛解毒的功效，能够促进组织再生、治疗创面等。 行业分类 按照保健食品剂型的 ...

吉林敖东药业集团股份有限公司（以下简称"公司"）于 2016 年 7 月 15 日 召开的 2016 年第一次临时股东大会审议通过了《<吉林敖东药业集团股份有限公 司员工持股计划（草案）>及其摘要》的议案，具体内容详见 2016 年 6 月 30 日、 2016 年 7 月 16 日在《中国证券报》《上海证券报》《证券时报》《证券日报》 及巨潮资讯网（http://www.cninfo.com.cn）披露的相关公告。 鉴于公司第一期员工持股计划存续期将于 2025 年 12 月 8 日届满，根据中国 证券监督管理委员会《关于上市公司实施员工持股计划试点的指导意见》、深圳 证券交易所《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规 范运作》相关规定，上市公司应当在员工持股计划届满前六个月公告即将到期的 员工持股计划所持有的股票数量及占公司股本总额的比例，现将相关情况公告如 下： 一、本次员工持股计划存续期内的持股情况 1.公司于 2016 年 7 月 15 日召开的 2016 年第一次临时股东大会审议通过了 《<吉林敖东药业集团股份有限公司员工持股计划（草案）>及其摘要》的议案， 具体内容详见 ...

鸿路钢构：全资子公司签订4.58亿元经营合同 6月3日晚，鸿路钢构（002541）发布公告称，全资子公司安徽鸿翔建材有限公司近日与中国十七冶集团 有限公司签订振石绿色高端镍铬新材智造项目钢结构成品采购合同，暂估价为4.58亿元。 资料显示，鸿路钢构成立于2002年9月，主营业务是钢结构及配套产品制造业务以及钢结构装配式建筑 工程业务。 所属行业：建筑装饰–专业工程–钢结构 风范股份：中标2.28亿元国家电网特高压项目 6月3日晚，风范股份（601700）发布公告称，公司在国家电网有限公司2025年第十五批采购（特高压项 目第二次材料招标采购）活动中中标，中标金额约2.28亿元，约占公司2024年经审计营业收入的 7.08%。 资料显示，风范股份成立于1993年7月，主营业务是角钢塔、钢管塔、成方焊管、钢结构件、单晶电池 片、单晶硅片等的生产与销售。 所属行业：电力设备–电网设备–线缆部件及其他 华生科技：监事及高管拟合计减持不超过0.1545%公司股份 6月3日晚，华生科技（605180）发布公告称，公司财务负责人范跃锋、副总经理范跃飞因个人资金需 求，计划通过集中竞价方式分别减持不超过9.83万股和9.11 ...

Core Viewpoint - Jilin Aodong (000623) announced that its subsidiary Yanbian Pharmaceutical has obtained 25 listings for traditional Chinese medicine formula granules, which will positively impact the company's expansion in this business segment and enhance its core competitiveness [1] Group 1: Company Developments - Yanbian Pharmaceutical has received a total of 525 listing certificates for traditional Chinese medicine formula granules as of the announcement date [1] - The newly obtained products include Jiu Bi Ying, American ginseng, Huoxiang, and fried rice sprouts [1] Group 2: Market Impact - The sales performance of the newly listed products may be influenced by changes in the market environment, indicating potential uncertainties [1] - The short-term impact on the company's overall performance is not expected to be significant [1]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，吉林敖东药业集团股份有限公司（以下简称"公司"）控股子公司吉 林敖东延边药业股份有限公司（以下简称"延边药业"）获得25个《中药配方颗 粒上市备案凭证》，现就相关情况公告如下： 证券代码：000623 证券简称：吉林敖东 公告编号：2025-030 吉林敖东药业集团股份有限公司 关于控股子公司获得中药配方颗粒上市备案凭证 的自愿性信息披露公告 一、《中药配方颗粒上市备案凭证》的主要内容 根据《中华人民共和国药品管理法》《中华人民共和国药品管理法实施条例》 等法律和法规的规定，对延边药业的以下产品予以备案： | 序号 | 名称 | 备案号 | | --- | --- | --- | | 1 | 救必应配方颗粒 | 上市备字2225000023000 | | 2 | 西洋参配方颗粒 | 上市备字2225000036000 | | 3 | 藿香配方颗粒 | 上市备字2225000066000 | | 4 | 炒稻芽配方颗粒 | 上市备字2225000067000 | | 5 | 六月雪（六月雪）配方颗粒 | 上市 ...

Summary of Jilin Aodong Pharmaceutical Group Conference Call Company Overview - Jilin Aodong Pharmaceutical Group Co., Ltd. was established in 1957 and has developed into a holding company with multiple subsidiaries in pharmaceuticals, medical research, and sales, among others [3][4][6] - The company operates under a "pharmaceutical + finance" dual-driven model and has a comprehensive supply chain involving planting and breeding bases [3][4] Key Points from the Conference Call Governance and Operational Efficiency - The company has received multiple governance honors in 2024, including recognition for its board practices, which have contributed to improved operational performance [6] - Continuous improvement of corporate governance structures and internal controls has been emphasized to ensure accurate information disclosure and enhance investor returns [6] Multi-Drive Development Model - The company is focused on a "pharmaceutical + finance + health" multi-drive development model, enhancing synergy and resource sharing across its various segments [7][8] - Marketing strategies have been optimized to align with national pharmaceutical policies, enhancing the efficiency of academic promotion and channel management [8] Market Expansion and Product Development - Jilin Aodong is actively exploring international markets while maintaining steady growth in its pharmaceutical core business [9][10] - The company has optimized its chemical drugs and retail pharmacy businesses, leveraging e-commerce platforms for sales growth [10][11] Financial Performance - In 2024, the company reported a revenue of 2.61 billion yuan, a decrease of 24.31% year-on-year, while net profit increased by 6.27% to 1.55 billion yuan [13][14][36] - The traditional Chinese medicine segment remains the largest contributor, accounting for 61.50% of total revenue [14][31] R&D and Innovation - R&D investment in 2024 was approximately 99.91 million yuan, a decrease of 29.69% from the previous year, with a focus on balancing R&D spending with cost control [32][33] - The company is committed to modernizing traditional Chinese medicine through innovative research and development, particularly in areas like cancer and cardiovascular diseases [33][42] Brand and Market Positioning - The "Aodong" brand has been recognized as a famous Chinese trademark and has a brand value of approximately 11.68 billion yuan [15][16] - The company aims to enhance its market share through targeted marketing strategies and maintaining high product quality [15][43] Challenges and Strategic Responses - The company faces challenges such as industry competition and product homogenization, which it addresses through differentiated marketing strategies and quality management [43] - Plans for 2025 include focusing on core products, optimizing shareholder returns, and enhancing market confidence through effective management practices [38][39] Future Outlook - The company is optimistic about growth in 2025, focusing on expanding its core product lines and enhancing R&D capabilities to meet market demands [41][42] - Jilin Aodong aims to leverage its strengths in traditional Chinese medicine and health products to capture emerging market opportunities [41][42] Additional Important Information - The company has implemented a cash dividend plan for 2024, distributing 3 yuan per 10 shares, balancing shareholder returns with capital needs [20][21] - The first quarter of 2025 saw a revenue of 623 million yuan, a decline of 27.71%, but net profit surged by 259.75% due to investment gains [22][23] This summary encapsulates the key insights and strategic directions discussed during the conference call, highlighting Jilin Aodong's operational strategies, financial performance, and future growth plans.

Core Insights - The company is focusing on expanding its online sales through major e-commerce platforms like JD.com, Taobao, and Pinduoduo, while also enhancing its O2O (Online to Offline) business model to seek new growth points [1] - A new pharmaceutical marketing management center has been established to strengthen professional service capabilities, with measures in place to revitalize slow-moving and unsold products [1] - The company aims to create a closed-loop ecosystem in the pharmaceutical industry by enhancing product supply from its manufacturing segment and improving customer retention through membership and pharmaceutical services [1] Sales and Marketing Strategy - The company is consolidating its market position for key products like injection-grade ribonucleic acid II through a clinical-to-terminal sales model and optimizing performance assessments for clinical personnel [1] - Plans include hosting marketing summits and academic seminars to cover hospital terminals and promote resource coverage nationwide [1] - The company is accelerating market penetration for selected products through centralized procurement and aims to achieve sales growth with newly approved products [2] Research and Development - The company is actively exploring traditional Chinese medicine and conducting research in various therapeutic areas, including cancer, kidney disease, diabetes, and cardiovascular diseases [3] - Multiple generic drug approvals have been obtained, including phosphoric acid oseltamivir capsules and others, indicating a steady progression in R&D projects [3] Technological Integration - The company is leveraging AI technology to optimize drug screening and clinical trial design, moving towards a smart manufacturing model that emphasizes high quality and efficiency [4] - A marketing reform initiative has been launched to establish a unified command and collaborative marketing system, enhancing strategic coordination and operational awareness across the organization [4]

Governance and Management - Jilin Aodong has received multiple governance honors, including the 2024 Excellent Board Practice Case, highlighting its commitment to corporate governance and operational performance improvement [2][3] - The company has established a robust governance structure and internal control management system to ensure accurate and complete information disclosure [2][3] Financial Performance - In 2024, the company achieved a revenue of CNY 261,057.51 million, a decrease of 24.31% compared to the previous year, while net profit attributable to shareholders increased by 6.27% to CNY 155,139.31 million [7][14] - The cost of the pharmaceutical segment decreased by 12.56% year-on-year, indicating effective cost management strategies [6][14] Business Segments - The three main business segments—traditional Chinese medicine, chemical pharmaceuticals, and retail pharmacy—generated a combined revenue of CNY 227,376.10 million, accounting for 87.10% of total revenue [7][11] - The traditional Chinese medicine segment alone contributed CNY 160,554.13 million, representing 61.50% of total revenue [7][9] Marketing and Sales Strategies - The company is enhancing its marketing system by integrating online sales through major e-commerce platforms and optimizing its offline stores for O2O business [5][11] - A focus on core product matrix development and strategic marketing initiatives has been implemented to improve sales performance and market penetration [10][11] Research and Development - In 2024, R&D investment amounted to CNY 99,909,053.79, a decrease of 29.69% from the previous year, with a focus on balancing R&D spending and cost control [17][19] - The company is actively pursuing innovation in traditional Chinese medicine and exploring new product development in various therapeutic areas [19][20] Shareholder Returns - The company plans to distribute a cash dividend of CNY 3 per 10 shares for 2024, reflecting a commitment to shareholder returns while balancing operational needs [12][13] - A three-year shareholder return plan has been established to enhance dividend frequency and optimize payout ratios [12][13] Challenges and Future Outlook - The company faces challenges such as declining revenue and increasing accounts receivable relative to revenue, prompting a focus on risk management and operational efficiency [16][21] - Future strategies include enhancing core product market share, expanding into international markets, and leveraging AI technology for operational improvements [20][21]